Slide 1: Ipsen Q1 2019 Sales
Ipsen Q1 2019 Sales April 24, 2019 Marin Living with fibrodysplasia ossificans progressiva Hamilton, Canada
Slide 2: Disclaimer & Safe Harbor
Disclaimer & Safe Harbor This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements, targets and estimates contained herein are for illustrative purposes only and are based on management’s current views and assumptions. Such statements in
Slide 3: Execution on growth strategy
Execution on growth strategy ▪ Focused execution to drive three-fold growth strategy: Top-line, bottom-line and pipeline ▪ Strong Q1 2019 Group sales growth of +15.8%1 driven by continued momentum of Specialty Care (+17.6%1) across all major products and geographies ▪ Confirmation of 2019 financial
Slide 4: Group sales growth driven by Specialty Care
Group sales growth driven by Specialty Care Group sales Net sales of key products in Q1 2019 in million euros – % excluding foreign exchange impact €597m SomatulineSomatuline ® +15.8%1 236 +16% Decapeptyl Decapeptyl® 89 +6% Specialty CabometyxCabometyx ® 54 +91% Specialty Care sales Care €531m Onivy
Slide 5: Q1 2019 performance highlights for key products
Q1 2019 performance highlights for key products Oncology Neuroscience Consumer Healthcare Somatuline® Dysport® ▪ Smecta® solid growth and • U.S. growth of 22.7% driven by volume and steady • Good growth in most strong in-market demand market share gains despite inventory build at the therapeutics ma
Slide 6: Acquisition of Clementia: Accelerating Ipsen's transformation
Acquisition of Clementia: Accelerating Ipsen’s transformation ▪ Acquisition: Announced 25 February and closed 17 April ▪ Palovarotene: Late-stage clinical asset for the treatment of rare bone disorders, adding a strong anchor asset to Ipsen’s Rare Diseases portfolio ▪ Upcoming milestones: Regulatory
Slide 7: Executing on 2019 objectives
Executing on 2019 objectives Growth Pipeline Culture Identify, execute Maximize growth Continue and integrate and market Leverage Increase value successful Drive further Consumer share worldwide commercial of the pipeline business transformation and Healthcare for differentiated capabilities and by
Slide 8: MERCI
MERCI Marin Living with fibrodysplasia ossificans progressiva Hamilton, Canada 8